GSK's London-listed shares fell about 2% on Friday after the U.S. Food and Drug Administration approved only one of two ...

Food and Drug Administration has approved British drugmaker GSK's blood cancer drug, Blenrep, in combination with other ...

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) today welcomed a new £6 million investment by GSK plc (LSE/NYSE: GSK) and ViiV Healthcare, the global specialist HIV company ...

London: GSK plc has received approval from the US Food and Drug Administration (FDA) for Blenrep (belantamab mafodotin-blmf) ...

The Global Fund has welcomed a £6 million joint investment from GSK and ViiV Healthcare to strengthen community-led responses ...

On Monday, Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga Pro. Activist investor Starboard Value has invested approximately $1 billion ...

British pharmaceutical firm GSK has pledged to invest $30bn (£22bn) in research and manufacturing in the US over the next five years. Announced at the start of US President Donald Trump's visit to the ...

Unlike peers, GSK plc faces limited Loss of Exclusivity risk, supporting steady revenue projections and justifying higher valuation multiples. Learn more about GSK stock here.

GSK’s London-listed shares fell even more swiftly than their ADRs to news that advisers to the Centers for Disease Control and Prevention shifted their recommendations for who should be vaccinated ...

GSK chief executive Emma Walmsley is to step down after more than eight years running the pharmaceuticals giant. Chief commercial officer Luke Miels will take on the role from the start of next year.